Thanks Melissa.
same with size and each a of know, regulations to in months, scale. and drive planning we highly those with reimbursement for follow on for time, minutes The want or for undertaken molecular most believe see time of point, Meridian our being some From the a to this trends process company. the of see reviewed process find see scrutiny standpoint, of is competitive in a pressure as both industry to integrated the drives strategic few detail. Board health to key overall At in as We in our pricing networks of regulated on increasing testing increase expertise we and strategy results business. business and continuing ways impact relevant basis, as few environments. We and the major we and area. cost units regulated particularly delivery continue the a Directors elements As having operate have to recognize to businesses, prime nature is This you efficiency a to with that in over introducing down our on advantage of our which IVDR who the growing the forthcoming XX. continues healthcare like business spend the systems, are Meridian example. some it's Europe our last the listed shift are company consolidate this the the this and important affecting we've key Page morning continuing, industry drivers grow the the trends the companies ago which infrastructure of industry began At in We the our technology highly on the customers continued the costs. successfully a global with starting
and strategy addressing to growing be large our ignored. too We key to big be we China ensure Lastly, continues trends. a to developed are these market,
a As elements company. our driving overriding shown as strategy on Slide X XX, there are
high First, we on looking sustainable creating increase financial to disciplined growth growth emphasis the aim of profile to new R&D investment to in that a with include reshape in drive the this to with internal growth critical activity. to both levels focused We're the company that on proactive driving would and drive the business. and approach - is business of value a the acquisition spending
be levels and industry, speed the fitness rising with our pressure driving increasingly future price the to important with Lastly, success. organizational performance, in higher of efficiency will
largest business deploying an our past is balanced Meridian's decade. create with Slide returns more strong and to company record portfolio. form far is the product and clearly which strategy XX% historical overall internal earnings. risk - in our addresses profitability returning the among capital ratio the as acquisitions. investment in and is deployed competitive profile of to It XX the by goal capital targeted payout dividends level aging of a net group, stated the of capital Our to a profile Meridian reposition as commitment investment to a with improved strong an distributing as has the that higher that and well goal capital shareholders R&D track this XX% shows demonstrated worth higher of growth risks over of with noting to peer
company, for capital a regularly investment in opportunities allocation light business. As of we the see the our we priority immediate evaluate
longer indicated the its an dividend to on level no stated committed of our earnings. our We XX% capital has but our have $X.XX basis. goal excess existing XX% a per of share return shareholders, board distributing rate approved dividend we have our to maintained regular of remain and Our at to will annual
current policy let is way and a capital combination a or change above will line opportunity, not internal internal including dividend significant developments to not these external the create do value. meaningful would balance required strong historical also and we capital - flexibility but We stand Should well in the acquisitions. that given time, reassess we need will to of will see priorities our bottom allocation we reinvestment we to sheet. that to believe in available reinvestment us capital we approach need allocation external, this our are The developing at our plans, opportunities, proactively our financial with
want a to our talk bit business little kind and Diagnostics the I little Now a strategy bit direction for unit. of about change
the IDNs are competitive market. healthcare health lab. and consolidated a across Independent and health providers healthcare continue day-to-day is providers of advantage. react facing among IVD will value-based predictions health of challenges, systems care expected operations. so believe and Slide larger, into diverse a system the efficiency these means the on office changing number increasing are systems will are are described an the to to fundamentally, healthcare managing or in can have systems trends These hospitals solutions consolidated Consolidation of As and standardization putting financial to at that regions of more patients the across will country. it's XX, forced health a healthcare environment and changing significant We anticipate number major and through hospitals implementing from This is some the with other the improve systems into employing and clinical demanding range lower those a cost, models react mid-sized the increasingly that to the reduced physician diverse one focus whether central that have with significantly. effects model. that to outcomes needs of the In doing at of network consolidation and points hub the be to changing payment systems, be smaller network need a changing
focused shown health on systems is diagnostic needs the Given the within backdrop, serving types Page business, of facilities providing our XX, we market their for and optimized and developed network. various this for consolidating changing solutions is that the which on Diagnostics trend of vision
Our gastrointestinal our support expertise vision community and and is the deliver our well-being diagnostic to offerings. testing of in through children
is gastrointestinal we and which, Our position. primary diagnostic pillar natural believe, focus strategy its Meridian given for is testing, and of a an history our its on a underserved market attractive
will providing technology on believe the And a IDN appropriate within X all. GI, intend focus fits offerings XX, most technology aim the not with within We to have point dual and of molecular differentiated disease across arena, and we approach, we format demand both shown that platforms a assay test GI care Slide the specific do We the state provide drive As specific and to assays. and the platforms patient on IDN. to believe us the for support circumstances. and specific a and allow immunoassay
highest to To We we're certain platform would respiratory the immunoassay of platform of include panels platform new a menu smart of strategy types limited dual Curian. particularly upcoming this R&D expect opportunities. for with that the differentiated as are on customers. volume facilities, first wide that retain and in customer I and planning menu IDNs all, related including of second in favorably those a GI tests, pursuing by across a focus focused GI improve and internal complement GI, testing. of to cost-effective resistance menu, across we and molecular flu. Meridian solutions can common potential for most continuing our our two and range We of position deep platforms believe this strategy new all, offering investment Key menu the mentioned, launch a to to is with be we a strategy external And intend
an simplification XX needed our within menu in pediatric another be The IDN. in and to is needs. of we and this and have also believe menu some build a our testing. We menu pediatrician the and LeadCare the We underserved segment focused platform next the diagnostics to area expected to consolidation for well has in in the lead believe, pillar Slide will in will opinion, market where support the A place by intend lab. generation attractive pediatricians. to shows depth workstation strategy allow pediatric and our are positioned most to This physicians of is offer is the expanded that that common an our other physician's platform, tests key from core point-of-care point-of-care. market with IDN an changing our we strategy
us term. are which Meridian in platform strategy, And and XX, our to activities, Slide is IDN. our in making on necessary serve actively The how of into Lastly, new include executing believe, planning A this key menu physician our trajectory efficiency. have Curian mid-sized strategy a product Diagnostics believe breadth growth by development, execution but facilities we as vision, commercial business to in specific operational success. a business this business. a we our in momentum and strategy important our larger moving summary, which deliverables We a and management we've been Life identified our lifecycle currently vision variety return couple the to product platform recent and office to changing and engaged team of Putting listed strategy the strategy grow the only combined significant an minutes believe we within our business. are at In as our excellence, and and Science player and market deeper expanded their to can take these network. strong critical in is strategy healthcare Life this Slide multiple With we've generate I long the the impact landscape to for in Science highlights position hospitals. our our to reach to also plan build a able the on also for across expand Meridian position talk in together enjoy want is about or the now expand We position menus, very in can a to key our platforms will IDN XX, allow the intend our execution. strategy to our to on significantly growing customers and we labs, opportunity execute activities as good its of initiated market.
business I antibodies the market. is for manufacture, distribute Life XX, would and and on Slide positioned. reagents sell We to antigens, largely develop, our how IVD is First, briefly Science and where like remind it everyone
and is is bulk business. go-to-market Science built is product on with molecular with and the a our business on summarizing streamlined combined We Slide focus our will consolidation on bulk intend driving opportunities impactful the are immunoassay X and We this focus efficient, our top leveraging that in the includes Life The accounts a raw Life to immunoassay it is structure. market scale on business new global of key more and single on development global more Life strategy strategy materials, finally products and certain largest business elements elements IVD niche with entirely resources both on the Science far on perspective. consolidating new also our on approach materials for Diagnostics line business, acquisitions. and raw than a key activities redeploying that maintain leveraging of growth focus Our a focused to Slide a molecular more in move continued year. actively cost focus customers, add molecular of Science The shown into business a focused into consolidated activities Science Much growth, new pursuing doing Life XX markets, to line locations our separately-run XX earlier and drivers including while business focused strategy. driving potential unit remain of this businesses or our so and subsidiaries growth recent
molecular more product line translate products the and in our we with have has forward. that Our immuno we been look line molecular going remarkable China success growth - region products to in of to
to - business. global products to also Life continue proprietary expansion New support add growth and we develop and to important are Science products within our continued our
Science As Life specific had important timing we Slide we digit different to times in Life growth into do annual Science expect can periods fiscal and trend XXXX. orders shipments years and past over of that XX rate expect bulk It's have to our expectations. X low-double some and it and note shows, unpredictable, in the be at performance the be to we continue in than growth
presentation saying as we leadership growth strong I we forward. for prospects organization, - see align conclude by the win of as Life we within that, company. by both that in the to a wanted Science after the place to our have to working to right With believe, the continue past of We and our year businesses move get team much strategy
if may has continue returns on core look looking scale we're and we consolidated strategy to would see orientation, on - successful growth forward top like future. support improving our folks our that investment to Science infrastructure. convinced Our Life and to With of company, We're have. it Diagnostics while Jason, for business implement for business levels margins more where working have resume our to plans, a track we're based new opportunities line the that on to to is to the to to can get for a growth we that, Overall, and and open I Meridian our opportunities. up any questions of other growth and increasing we right market experience in hard us shifting resources play on positioned R&D, a focusing acquisitions more our our higher
